Converting medical waste to therapeutics for all: Zami Aberman, CEO and Chairman, Pluristem




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Converting medical waste to therapeutics for all: Zami Aberman, CEO and Chairman, Pluristem
Released on: May 29, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In cell therapy the process is the product.
  • Summary
  • Transcript
  • Participants
  • Company
In cell therapy the process is the product. Pluristem’s 3D expansion technology allows for the production of different PLX cell products. . Pluristem manufactures therapeutic cell products using human placental cells harvested from donated placentas. The placentas are acquired from mothers, who undergo a scheduled caesarean section and have been prescreened by Pluristem. The placenta is typically discarded after delivery, making it a readily available source of mesenchymal like adherent stromal cells. Cells can be harvested from it without raising controversial ethical issues, and no invasive procedures, such as bone marrow collection, are required. Zami Aberman, CEO and Chairman, Pluristem explains to Fintan Walton how they are affectively developing 'a cell therapy product in a bottle' He also discusses how in their work on pre eclampsia they are using the byproduct of one healthy birth to enable another one.
In cell therapy the process is the product. Pluristem’s 3D expansion technology allows for the production of different PLX cell products. . Pluristem manufactures therapeutic cell products using human placental cells harvested from donated placentas. The placentas are acquired from mothers, who undergo a scheduled caesarean section and have been prescreened by Pluristem. The placenta is typically discarded after delivery, making it a readily available source of mesenchymal like adherent stromal cells. Cells can be harvested from it without raising controversial ethical issues, and no invasive procedures, such as bone marrow collection, are required. Zami Aberman, CEO and Chairman, Pluristem explains to Fintan Walton how they are affectively developing 'a cell therapy product in a bottle' He also discusses how in their work on pre eclampsia they are using the byproduct of one healthy birth to enable another one.
Zami Aberman
Pluristem
Pluristem Therapeutics inc.
Pluristem Therapeutics Inc. is a bio-therapeutics Company, dedicated to giving patients a better chance to recover from a variety of severe degenerative, malignant and autoimmune disorders through the commercialization of unrelated donor-patient (allogeneic) stem cell therapy products. Pluristem has made the strategic decision to work only with adult stem cells, purified from the placenta after birth and, therefore, not subject to ethical or religious controversy. Pluristem’s vision is one of commitment, integrity, teamwork, inspiration, novelty and quality. We lead by example and expect others to maintain these high standards. As individuals and as an organization we strive to perform to our maximum abilities for the common good of ourselves, our shareholders’ and those who need and use our products.